Second cancers in survivors of childhood cancer (original) (raw)

• Neugut, A. I., Meadows, A. T. & Robinson, E. (eds). Multiple Primary Cancers 1999 3–10 (Lippincott Williams & Wilkins, Philadelphia, 1999).
  Google Scholar
• Sklar, C. A. Overview of the effects of cancer therapies: the nature, scale, and breadth of the problem. Acta Paediatr Suppl 88, 1–4 (1999).
  CAS PubMed Google Scholar
• Neglia, J. P. et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J. Natl Cancer Inst. 93, 618–629 (2001).In a large cohort of five-year survivors of childhood cancer, the authors describe the incidence of second cancers, characterize the second cancers and describe the risk factors associated with their development.
  CAS PubMed Google Scholar
• Bhatia, S. et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N. Engl. J. Med. 334, 745–751 (1996).The authors describe the incidence and risk factors associated with the development of second primary breast cancer and other second cancers in a large multinational cohort of childhood Hodgkin's disease survivors followed for an extended period of time.
  CAS PubMed Google Scholar
• Meadows, A. T. Risk factors for second malignant neoplasms: report from the Late Effects Study Group. Bull. Cancer 75, 125–130 (1988).
  CAS PubMed Google Scholar
• Neglia, J. P. et al. Second neoplasms after acute lymphoblastic leukaemia in childhood. N. Engl. J. Med. 325, 1330–1336 (1991).
  CAS PubMed Google Scholar
• Boice, J. D. Jr, Land, C. E. & Preston, D. L. in Cancer Epidemiology and Prevention (eds Schottenfeld, D. & Fraumeni, J. F. Jr) 319–354 (Oxford Univ. Press, New York, 1996).
  Google Scholar
• Preston, D. et al. Cancer incidence in atomic bomb survivors. III. Leukaemia, lymphoma, and multiple myeloma, 1950–1987. Radiat. Res. 137, S68–S97 (1994).
  CAS PubMed Google Scholar
• Thompson, D. E. et al. Cancer incidence in atomic bomb survivors. II: solid tumours, 1958–1987. Radiat. Res. 137, S17–S67 (1994).
  CAS PubMed Google Scholar
• Ron, E. et al. Radiation-induced skin carcinomas of the head and neck. Radiat. Res. 125, 318–325 (1991).
  CAS PubMed Google Scholar
• Wong, F. L. et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278, 1262–1267 (1997).In a large cohort of patients with retinoblastoma, diagnosed between 1914 and 1984, the authors describe the incidence and risk factors of second cancers and show that genetic predisposition has a substantial impact on the risk of subsequent cancers, which is further increased by radiation therapy.
  CAS PubMed Google Scholar
• Strong, L. C., Stine, M. & Norsted, T. L. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J. Natl Cancer Inst. 79, 1213–1220 (1987).
  CAS PubMed Google Scholar
• Land, C. E. et al. Incidence of salivary gland tumours among atomic bomb survivors, 1950–1987. Evaluation of radiation-related risk factors. Radiat. Res. 146, 28–36 (1996).
  CAS PubMed Google Scholar
• Sankila, R., Pukkala, E. & Teppo, L. Risk of subsequent malignant neoplasms among 470,000 cancer patients in Finland, 1953–1991. Int. J. Cancer 60, 464–470 (1995).
  CAS PubMed Google Scholar
• Dong, C. & Hemminki, K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996. Int. J. Cancer 93, 155–161 (2001).
  CAS PubMed Google Scholar
• Curtis, R. E., Boice, J. D. Jr Kleinerman, R. A., Flannery, J. T. & Fraumeni, J. F. Jr. Summary: multiple primary cancers in Connecticut, 1935–1982. Natl Cancer Inst. Monogr. 68, 219–242 (1985).
  CAS PubMed Google Scholar
• Olsen, J. H. et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ 307, 1030–1036 (1993).
  CAS PubMed PubMed Central Google Scholar
• Reis, L. A. G. et al. (eds). SEER Cancer Statistics Review, 1973–1998, National Cancer Institute. (National Cancer Institute, Bethesda, Maryland, 2001).
• Bhatia, S. et al. Malignant neoplasms following bone marrow transplantation. Blood 87, 3633–3639 (1996).
  CAS PubMed Google Scholar
• Darrington, D. L. et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukaemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J. Clin. Oncol. 12, 2527–2534 (1994).
  CAS PubMed Google Scholar
• Zang, E. A. & Wynder, E. L. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl Cancer Inst. 88, 183–192 (1996).
  CAS PubMed Google Scholar
• Breslow, N. E. et al. Second malignant neoplasms following treatment of Wilm's tumour: a report from the National Wilms' Tumour Study Group. J. Clin. Oncol. 13, 1851–1859 (1995).
  CAS PubMed Google Scholar
• Hawkins, M. M. et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J. Natl Cancer Inst. 88, 270–278 (1996).In a large population-based cohort study, the authors report a low incidence of bone tumours among three-year survivors of childhood cancer, except following hereditary retinoblastoma, Ewing's sarcoma and other malignant bone tumours. They show the dose–response relationship of the second primary bone tumours with increasing doses of radiation, and the association of second primary bone tumours with alkylating agents.
  CAS PubMed Google Scholar
• Garwicz, S. et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case–control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int. J. Cancer 88, 672–678 (2000).The authors carried out a nested case–control study within a Nordic cohort of 25,120 patients to assess the risk factors associated with the development of second primary cancers following a first primary cancer in childhood. Radiation therapy was the most important treatment-related risk factor identified.
  CAS PubMed Google Scholar
• Tucker, M. A., D'Angio, G. J., Boice, J. D. Jr et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J. Med. 317, 588–593 (1987).
  CAS PubMed Google Scholar
• Hancock, S. L., Tucker, M. A. & Hoppe, R. T. Breast cancer after treatment of Hodgkin's disease. J. Natl Cancer Inst. 85, 25–31 (1993).
  CAS PubMed Google Scholar
• Metayer, C. et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J. Clin. Oncol. 18, 2435–2443 (2000).
  CAS PubMed Google Scholar
• Kaste, S. C. et al. Breast masses in women treated for childhood cancer: incidence and screening guidelines. Cancer 82, 784–792 (1998).
  CAS PubMed Google Scholar
• Travis, L. B., Curtis, R. E. & Boice, J. D. Jr. Late effects of treatment for childhood Hodgkin's disease. N. Engl. J. Med. 334, 745–751 (1996).
  Google Scholar
• De Vathaire, F. et al. Thyroid carcinomas after irradiation for a first cancer during childhood. Arch. Intern. Med. 159, 2713–2719 (1999).
  CAS PubMed Google Scholar
• Sklar, C. et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 85, 3227–3232 (2000).
  CAS PubMed Google Scholar
• Loning, L. et al. Secondary neoplasms subsequent to Berlin–Frankfurt–Munster therapy of acute lymphoblastic leukaemia in childhood: significantly lower risk without cranial radiotherapy. Blood 95, 2770–2775 (2000).The authors followed a large cohort of patients treated for ALL in childhood on Berlin-Frankfurt–Munster (BFM) therapeutic protocols, and showed that the incidence of second cancers is relatively low, except among patients receiving cranial irradiation.
  CAS PubMed Google Scholar
• de Vathaire, F. et al. Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br. J. Cancer 79 1884–1893 (1999).
  CAS PubMed Google Scholar
• Smith, M. A. et al. Secondary leukaemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J. Clin. Oncol. 17, 569–577 (1999).The Cancer Therapy Evaluation Program of the National Cancer Institute has developed a monitoring plan to describe the incidence of secondary leukaemia after epipodophyllotoxin treatment and the relationship between epipodophyllotoxin cumulative dose and risk of secondary leukaemia. The study failed to show a dose–response relationship between epipodophylltoxins and therapy-related leukaemia.
  CAS PubMed Google Scholar
• Pedersen-Bjergaard, J. et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 318 1028–1032 (1988).
  CAS PubMed Google Scholar
• Wolden, S. L., Lamborn, K. R., Cleary, S. F., Tate, D. J. & Donaldson, S. S. Second cancers following pediatric Hodgkin's disease. J. Clin. Oncol. 16, 536–544 (1998).
  CAS Google Scholar
• Sankila, R. et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries — Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J. Clin. Oncol. 14, 1442–1446 (1996).
  CAS PubMed Google Scholar
• Schellong, G. et al. Low risk of secondary leukaemia after chemotherapy without mechlorethamine in childhood Hodgkin's disease: German–Austrian Pediatric Hodgkin's Disease Group. J. Clin. Oncol. 15, 2247–2253 (1997).
  CAS PubMed Google Scholar
• Greene, M. H. et al. Melphalan may be a more potent leukaemogen than cyclophosphamide. Ann. Intern. Med. 105, 36–67 (1986).
  Google Scholar
• Tucker, M. A. et al. Leukaemia after therapy with alkylating agents for childhood cancer. J. Natl Cancer Inst. 78, 459–464 (1987).
  CAS PubMed Google Scholar
• Chabner, B. A. & Myers, C. E. in Principles and Practice of Oncology 2nd edn (eds DeVita, V.T., Hellman, S. & Rosenberg, S. A.) 349–395 (J. B. Lippincott, Philadelphia, 1989).
  Google Scholar
• Tew, K. D., Clovin, M. & Chabner, B. A. in Cancer Chemotherapy and Biotherapy: Principles and Practice Vol. 1 (eds Chabner, B. A. & Longo, D. L.) 297–232 (Lippincott-Raven Publishers, New York (1996).
  Google Scholar
• Karp, J. E. & Smith, M. A. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin. Oncol. 24, 103–113 (1997).
  CAS PubMed Google Scholar
• Pui, C.-H. et al. Acute myeloid leukaemia in children treated with epipodophyllotoxins for acute lymphocytic leukaemia. N. Engl. J. Med. 325, 1682–1687 (1991).Pui et al . assessed the risk of therapy-related AML among children with ALL treated with epipodophyllotoxins, and showed that the risk of epipodophyllotoxin-related leukaemia depended largely on the schedule of drug administration.
  CAS PubMed Google Scholar
• Winick, N. J. et al. Secondary acute myeloid leukaemia in children with acute lymphoblastic leukaemia treated with etoposide. J. Clin. Oncol. 11, 209–217 (1993).
  CAS PubMed Google Scholar
• Sugita, K. et al. High frequency of etoposide (VP-16)-related secondary leukaemia in children with non-Hodgkin's lymphoma. Am. J. Pediatr. Hematol. Oncol. 15, 99–104 (1993).
  CAS PubMed Google Scholar
• Hawkins, M. M. et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. BMJ 304, 951–958 (1992).The authors investigated the incidence and aetiology of secondary leukaemia after childhood cancer in a cohort of 16,422 patients diagnosed and treated in the United Kingdom, and showed that epipodophyllotoxins acting alone or together with alkylating agents or radiation seem to be involved in secondary leukaemia after childhood.
  CAS PubMed PubMed Central Google Scholar
• Corbett, A. H. & Osheroff, N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol. 6, 585–597 (1993).
  CAS PubMed Google Scholar
• Felix, C. A. Secondary leukaemias induced by topoisomerase targeted drugs. Biochim. Biophys. Acta 1400, 233–235 (1998).
  CAS PubMed Google Scholar
• Atlas, M. et al. Cloning and sequence analysis of four t(9;11) therapy-related leukaemia breakpoints. Leukemia 12, 1895–1902 (1998).
  CAS PubMed Google Scholar
• Megonigal, M. D. et al. Detection of leukaemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc. Natl Acad. Sci. USA 97, 2814–2819 (2000).
  CAS PubMed Google Scholar
• Lovett, B. D. et al. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukaemia-associated MLL translocation breakpoints. Biochemistry 40, 1159–1170 (2001).
  CAS PubMed Google Scholar
• Super, H. J. G. et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukaemia in patients previously treated with agents targeting DNA topoisomerase II. Blood 82, 3705–3711 (1993).
  CAS PubMed Google Scholar
• Felix, C. A. et al. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res. 55, 4287–4292 (1995).
  CAS PubMed Google Scholar
• Bower, M. et al. Human trithorax gene rearrangements in therapy-related acute leukaemia after etoposide treatment. Leukemia 8, 226–229 (1994).
  CAS PubMed Google Scholar
• Felix, C. A. et al. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukaemia. Cancer Res. 53, 2954–2956 (1993).
  CAS PubMed Google Scholar
• Broeker, P. L. S. et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukaemia and therapy-related acute myeloid leukaemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood 87, 1912–1922 (1996).
  CAS PubMed Google Scholar
• Hunger, S. P. et al. HRX involvement in de novo and secondary leukaemias with diverse chromosome 11q23 abnormalities. Blood 81, 3197–3203 (1993).
  CAS PubMed Google Scholar
• Andersen, M. K., Johansson, B., Larsen, S. O. & Pedersen-Bjergaard, J. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica 83, 483–488 (1998).
  CAS PubMed Google Scholar
• Jeha, S., Jaffe, N. & Robertson, R. Secondary acute nonlymphoblastic leukaemia in two children following treatment with a _cis_-diamminechloroplatinum-II-based regimen for osteosarcoma. Med. Pediatr. Oncol. 20, 71–74 (1992).
  CAS PubMed Google Scholar
• Ben-Yehuda, D. et al. Microsatellite instability and p53 mutations in therapy-related leukaemia suggest a mutator phenotype. Blood 88, 4296–4303 (1996).
  CAS PubMed Google Scholar
• Gafanovich, A. et al. Microsatellite instability and p53 mutations in pediatric secondary malignant neoplasms. Cancer 85, 504–510 (1999).
  CAS PubMed Google Scholar
• Hisada, M. et al. Multiple primary cancers in families with Li–Fraumeni syndrome. J. Natl Cancer Inst. 90, 606–611 (1998).
  CAS PubMed Google Scholar
• Swift, M., Morrell, D., Massey, R. B. & Chase, C. L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med. 325, 1831–1836 (1991).
  CAS PubMed Google Scholar
• Nichols, K. E. et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J. Clin. Oncol. 17, 1259 (1999).
• Shafman, T. D. et al. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contalateral tumour. Genes Chromosomes Cancer 27, 124–129 (2000).
  CAS PubMed Google Scholar
• Teraoka, S. N. et al. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer 92, 479–487 (2001).
  CAS PubMed Google Scholar
• Relling, M. V. et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354, 34–39 (1999).The authors assessed the clinical, biological and pharmacokinetic features among children with ALL receiving cranial radiotherapy, and showed that underlying genetic characteristics and treatment variables might be associated with an increased risk of radiation-associated brain tumours.
  CAS PubMed Google Scholar
• Relling, M. V. et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukaemia. Leukemia 12, 346–352 (1998).The authors assessed the pharmacological characteristics of patients who developed epipodophyllotoxin-related AML after ALL, and showed that patients with lower thiopurine methyltransferase activity were more likely to develop secondary AML in this setting.
  CAS PubMed Google Scholar
• Naoe, T. et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukaemia/myelodysplastic syndrome and de novo acute myeloid leukaemia. Clin. Cancer Res. 6, 4091–4095 (2000).
  CAS PubMed Google Scholar
• Chen, H. et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase θ1 (GSTT1) gene defect. Lancet 347, 295–297 (1996).
  CAS PubMed Google Scholar
• Felix, C. A. et al. Association of CYP3A4 genotype with treatment-related leukaemia. Proc. Natl Acad. Sci. USA 95, 13176–13181 (1998).The authors showed that individuals with the CYP3A4-W genotype might be at increased risk for treatment-related leukaemia and that epipodophyllotoxin metabolism by CYP3A4 might contribute to the secondary leukaemia by increasing production of potentially DNA-damaging reactive intermediates.
  CAS PubMed Google Scholar
• Hayes, J. D. & Pulford, D. J. The glutathione _S_-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30, 445–600 (1995).
  CAS PubMed Google Scholar
• Smith, G., Stanley, L. A., Sim, E., Strange, R. C. & Wolf, C. R. Metabolic polymorphisms and cancer susceptibility. Cancer Surv. 25, 27–65 (1995).
  CAS PubMed Google Scholar
• Raunio, H. et al. Diagnosis of polymorphisms in carcinogen activating and inactivating enzymes and cancer susceptibility. Gene 159, 113–121 (1995).
  CAS PubMed Google Scholar
• Wrighton, S. & Stevens, J. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1–21 (1992).
  CAS PubMed Google Scholar
• Allan, J. M. et al. Polymorphism in glutathione _S_-transferase P1 is associated with susceptibility to chemotherapy-induced leukaemia. Proc. Natl Acad. Sci. USA 98, 11592–11597 (2001).The authors assessed polymorphisms in glutathione S -transferases and sought to identify an association with therapy-related leukaemia. They showed that inheritance of at least one Val allele at GSTP1 codon 105 confers a significantly increased risk of developing therapy-related leukaemia after cytotoxic chemotherapy.
  CAS PubMed Google Scholar
• Woo, M. H. et al. Glutathione _S_-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 14, 226–231 (2000).
  Google Scholar
• Van Leeuwen, F. E. et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J. Natl Cancer Inst. 87, 1530–1537 (1995).This study investigated the effects of radiation dose, chemotherapy and smoking on the risk of lung cancer following treatment of Hodgkin's disease. The authors showed that the excess risk of lung cancer in patients with Hodgkin's disease who were treated with radiotherapy is related to the radiation dose received by the affected area of the lung. Moreover, smokers experience a significantly greater risk attributable to radiotherapy than non-smokers.
  CAS PubMed Google Scholar
• Boivin, J. F. Smoking, treatment for Hodgkin's disease, and subsequent lung cancer. J. Natl Cancer Inst. 87, 1502–1503 (1995).
  CAS PubMed Google Scholar
• Tucker, M. A. et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. J. Natl Cancer Inst. 89, 1782–1788 (1997).
  CAS PubMed Google Scholar
• Inskip, P. D. & Boice, J. D. Jr. Radiotherapy-induced cancer among women who smoke. Cancer 73, 1541–1543 (1994).
  CAS PubMed Google Scholar
• Neugut, A. I. et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 73, 1615–1620 (1994).
  CAS PubMed Google Scholar
• Jensen, O. M., Paine, S. L., McMichal, A. J. & Ewertz, M. in Cancer Epidemiology and Prevention 2nd edn (eds Schottenfeld, D. & Fraumeni, J. F.) 290–318 (Oxford, Oxford Univ. Press, 1996).
  Google Scholar
• Rothman, K. & Keller, A. Z. The effect of joint exposure to alcohol and tobacco on risk of cancers of the mouth and pharynx. J. Chronic Dis. 25, 711–716 (1972).
  CAS PubMed Google Scholar
• Flanders, W. D. & Rothman, K. J. Interaction of alcohol and tobacco in laryngeal cancer. Am. J. Epidemiol. 115, 371–379 (1982).
  CAS PubMed Google Scholar
• LaVecchia, C. & Negri, E. The role of alcohol in esophageal cancer in nonsmokers, and the role of tobacco in nondrinkers. Int. J. Cancer 43, 784–785 (1989).
  CAS Google Scholar
• van Leeuwen, F. E. et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J. Natl Cancer Inst. 87, 1530–1537 (1995).
  CAS PubMed Google Scholar
• Perera, F. P. Environment and cancer: who are susceptible? Science 278, 1068–1073 (1997).
  CAS PubMed Google Scholar
• Baron, J. A. & Rohan, T. E. in Cancer Epidemiology and Prevention 2nd edn (eds Schottenfeld, D. & Fraumeni, J. F.) 269–289 (Oxford, Oxford Univ. Press, 1996).
  Google Scholar
• Rothman, K. & Keller, A. Z. The effect of joint exposure to alcohol and tobacco on risk of cancers of the mouth and pharynx. J. Chronic Dis. 25, 711–716 (1972).
  CAS PubMed Google Scholar
• Flanders, W. D. & Rothman, K. J. Interaction of alcohol and tobacco in laryngeal cancer. Am. J. Epidemiol. 115, 371–379 (1982).
  CAS PubMed Google Scholar
• LaVecchia, C. & Negri, E. The role of alcohol in esophageal cancer in nonsmokers, and the role of tobacco in nondrinkers. Int. J. Cancer 43, 784–785 (1989).
  CAS Google Scholar
• Thomas, H. V., Reeves, G. K. & Key, T. J. Endogenous oestrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 8, 922–928 (1997).
  CAS PubMed Google Scholar
• Pike, M. C., Spicer, D. V., Dahmoush, L. & Press, M. F. Oestrogens, progesterone, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15, 17–35 (1993).
  CAS PubMed Google Scholar
• Bosland, M. C. The role of steroid hormones in prostate carcinogenesis. J. Natl Cancer Inst. Monogr. 27, 39–66 (2000).
  CAS Google Scholar
• Yu, H. & Rohan, T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst. 92, 1472–1489 (2000).
  CAS PubMed Google Scholar
• Sklar, C. A. Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr. Clin. N. Am. 44, 489–503 (1997).
  CAS Google Scholar
• Sklar, C. A. et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukaemia: role of cranial irradiation. Med. Pediatr. Oncol. 35, 91–95 (2000).
  CAS PubMed Google Scholar
• Tavani, A. et al. Risk factors for breast cancer in women under 40 years. Eur. J. Cancer 35, 1361–1367 (1999).
  CAS PubMed Google Scholar
• Willett, W. C., Dietz, W. H. & Colditz, G. A. Guidelines for healthy weight. N. Engl. J. Med. 341, 427–434 (1999).
  CAS PubMed Google Scholar
• Sklar, C., Boulad, F., Small, T. & Kernan, N. Endocrine complications of pediatric stem cell transplantation. Front. Biosci. 6, G17–G22 (2001).
• Bhatia, S., Sather, H. N., Trigg, M., Gaynon, P. & Robison, L. L. Low incidence of second neoplasms following childhood ALL: follow–up of the Children's Cancer Group Cohort. Presented at the American Society of Hematology Meeting, San Francisco, California, 2000.
• Bhatia, S., Krailo, M., Robison, L. L. & Meyers, P. Secondary myelodysplasia among survivors of osteosarcoma. Presented at the American society of Clinical Oncology Meeting, San Francisco, California, 2001.
• Krishnan, A. et al. Predictors of therapy-related leukaemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 95, 1588–1593 (2000).
  CAS PubMed Google Scholar
• Bhatia, S., Davies, S. M. & Robison, L. L. in Multiple Primary Cancers (eds Neugut, A. I., Meadows, A. T. & Robinson, E.) 257–275 (Lippincott Williams & Wilkins, Philadelphia, 1999).
  Google Scholar